Short Interest in Lantheus Holdings Inc (NASDAQ:LNTH) Declines By 8.2%

Lantheus Holdings Inc (NASDAQ:LNTH) saw a significant decrease in short interest in May. As of May 15th, there was short interest totalling 2,460,000 shares, a decrease of 8.2% from the April 30th total of 2,680,000 shares. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 445,400 shares, the short-interest ratio is presently 5.5 days.

NASDAQ LNTH traded up $0.06 on Friday, reaching $12.70. The company had a trading volume of 167,995 shares, compared to its average volume of 318,262. The firm has a market cap of $502.52 million, a price-to-earnings ratio of 10.11 and a beta of 1.28. Lantheus has a fifty-two week low of $8.67 and a fifty-two week high of $29.80. The business has a 50 day moving average of $12.61 and a two-hundred day moving average of $16.63. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.91 and a quick ratio of 2.41.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $0.36 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.07. The business had revenue of $90.70 million during the quarter, compared to the consensus estimate of $91.70 million. Lantheus had a return on equity of 46.94% and a net margin of 7.13%. Lantheus’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.28 earnings per share.

In other news, CEO Mary Anne Heino sold 9,898 shares of the company’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $16.06, for a total transaction of $158,961.88. Following the completion of the transaction, the chief executive officer now directly owns 556,014 shares in the company, valued at $8,929,584.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Julie Mchugh sold 1,756 shares of the company’s stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $15.86, for a total transaction of $27,850.16. Following the transaction, the director now owns 15,754 shares of the company’s stock, valued at $249,858.44. The disclosure for this sale can be found here. Insiders have sold 61,785 shares of company stock valued at $904,824 over the last quarter. Company insiders own 2.08% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Sunbelt Securities Inc. bought a new stake in Lantheus during the fourth quarter valued at $5,128,000. Meeder Asset Management Inc. boosted its position in Lantheus by 802.0% during the fourth quarter. Meeder Asset Management Inc. now owns 2,652 shares of the medical equipment provider’s stock valued at $55,000 after acquiring an additional 2,358 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Lantheus during the fourth quarter valued at $57,000. Aigen Investment Management LP bought a new stake in Lantheus during the fourth quarter valued at $67,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Lantheus by 99.7% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,438 shares of the medical equipment provider’s stock valued at $44,000 after acquiring an additional 1,716 shares during the last quarter. 95.34% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts recently weighed in on the company. BidaskClub downgraded Lantheus from a “hold” rating to a “sell” rating in a report on Friday, May 15th. ValuEngine upgraded Lantheus from a “sell” rating to a “hold” rating in a report on Saturday, February 15th.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.

See Also: Catch-Up Contributions

Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply